About US
Contact us
-
Ruling against GSK's Lovaza fish-oil pill puts hurt on competitor AmarinAmarin has been unable to get traction on Vascepa, and price competition could make it harder Poor Amarin ($AMRN) and its still unrealized hopes for its fish oil cholesterol pill,Vascepa. A U.S. appe2013/9/13
-
GlaxoSmithKline's approval streak helps ease scandal painGlaxoSmithKline ($GSK) has been having a year for the record book. And that's not entirely a good thing2013/9/13
-
CFDA Vice Minister Teng Jiacai meets Secretary General of Ministry of Plantation Industries and Commodities of Malaysia and Ambassador of Malaysia to ChinaOn September 10, 2013, Teng Jiacai, Vice Minister of China Food and Drug Administration (CFDA) met with the delegation led by Datin Paduka Nurmala, Secretary General of Ministry of Plantation Industri2013/9/12
-
CFDA Minister Zhang Yong meets Minister of Health, Welfare and Sports of the Netherlands and Ambassador of the Netherlands to ChinaOn September 10, 2013, Zhang Yong, Minister of China Food and Drug Administration (CFDA), met with the delegation led by Edith Schippers, Minister of Health, Welfare and Sports of the Netherland2013/9/12
-
FDA ratchets up requirements on long-acting, extended-release opioidsLabeling must indicate they are for severe pain only; drugmakers must do studies on abuse potential The FDA, under pressure to help curb abuse ofopioid painkillers, has taken yet another step to damp2013/9/11
-
Lilly's warehouse burglar targeted GlaxoSmithKline, tooA burglar who pulled off a bold warehouse theft at an Eli Lilly ($LLY) facility has now admitted that he made off with millions in GlaxoSmithKline ($GSK) products in a previous heist.2013/9/11
-
Bayer's Xarelto faces stepped-up reports of side effects, deathsThe number of side-effect reports onBayer's anticoagulant drugXareltoappears to be increasing, and some doctors are growing wary of using the drug as a standard first-line treatment,the German newspap2013/9/10
-
GSK unloading drinks brands to Japan's Suntory for $2.1BGlaxoSmithKline ($GSK) is slimming down again, this time with a long-anticipated deal to sell off two of its drinks brands. What was not anticipated was the price--£1.35 billion, or $2.11 billio2013/9/10
-
Celgene's Abraxane approved for first-line treatment of pancreatic cancerThe FDA today approved Celgene'sAbraxaneforpancreatic cancer, an approval that provides some hope for extending the lives of patients with the aggressive cancer. It should also significantly extend th2013/9/9
-
Mallinckrodt tamper-resistant drug performs well for bunion patientsMallinckrodt ($MNK) has released good-news data from a Phase III study of an experimental pain drug for use by patients after bunion surgery. In June, the Dublin, Ireland-based drugmaker submitted a n2013/9/9